Immunitybio Inc (IBRX) Peer Comparison

$9.91

$0.11 (1.12%)

As on 14-Oct-2026 16:44EDT

Market cap

$11,139 Mln

Revenue (TTM)

$166 Mln

P/E Ratio

--

P/B Ratio

0

Div. Yield

0 %

Edit

	Immunitybio Inc (IBRX)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Halozyme Therapeutics (HALO)
Market cap ($ Mln)	11,139	17,083	15,084	14,832	12,532
Revenue ($ Mln)	166	2,782	1,054	2,436	1,664
Net Profit ($ Mln)	-992.36	491.50	755.85	860.62	413.60
Net Margin (%)	-598.56	17.67	71.69	35.33	24.86
RoE (%)	--	110.09	--	42.98	430.03
Price to Earnings	--	35.94	17.57	18.88	32.29
Price-To-Book	--	39.70	8.91	7.82	88.91

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	Immunitybio Inc (IBRX)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Halozyme Therapeutics (HALO)
Operating Revenue	165.79	2,782.29	1,054.37	2,435.92	1,663.74
Cost of Revenue	8.91	1,982.07	103.47	85.67	292.42
Gross Profit	112.54	760.62	588.53	2,236.43	1,167.84
Operating Expenses	408.68	216.81	841.45	1,378.74	440.53
Operating Profit (EBIT)	-251.80	583.40	109.45	971.51	930.79
Other Income	0.00	0.00	0.00	0.00	0.00
Profit before Tax	-992.58	598.92	101.11	1,035.47	583.34
Provision for Tax	-0.18	107.42	-654.74	174.84	169.74
Profit after Tax (Net Income)	-992.36	491.50	755.85	860.62	413.60
Minority Interest	0.06	0.00	0.00	0.00	0.00
Consolidated Profit	0.00	0.00	0.00	0.00	0.00

Liabilities ($ Mln)

	Immunitybio Inc (IBRX)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Halozyme Therapeutics (HALO)
Shareholder's Funds	-1,046.63	433.86	1,435.90	1,843.76	143.54
Minority Interest	0.06	0.00	0.00	0.00	0.00
Non-Current Liabilities	1,597.54	187.89	384.48	288.55	2,089.43
Current Liabilities	76.73	1,435.43	464.70	361.93	344.44
Total Liabilities	501.90	1,975.47	1,302.02	2,844.42	2,525.32

Assets ($ Mln)

	Immunitybio Inc (IBRX)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Halozyme Therapeutics (HALO)
Non-Current Assets	189.52	1,006.90	895.24	1,243.41	1,644.38
Current Assets	438.98	1,050.29	1,389.84	1,250.82	933.02
Total Assets	501.90	1,975.47	1,302.02	2,844.42	2,525.32
Total Debt*	813.06	144.11	449.89	165.93	2,146.65
Net Current Assets	362.25	-385.14	925.52	888.90	588.59

Cashflow ($ Mln)

	Immunitybio Inc (IBRX)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Halozyme Therapeutics (HALO)
Cash From Operating Activities	-304.94	713.22	51.77	884.27	651.56
Cash Flow from Investing Activities	-149.80	-31.14	-8.15	350.44	-545.81
Cash from Financing Activities	400.24	-860.39	34.89	-969.59	-85.17
Net Cash Inflow / Outflow	--	--	--	--	--

Ratios

Profitability Ratios

	Immunitybio Inc (IBRX)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Halozyme Therapeutics (HALO)
ROCE (%)	-178.55	57.43	-30.01	32.82	15.61
ROE (%)	71.08	110.09	163.18	42.98	430.03
ROA (%)	-171.40	15.64	31.68	29.32	16.19
EBIT Margin (%)	-548.47	21.13	5.73	41.82	36.28
Net Margin (%)	-598.56	17.67	71.69	35.33	24.86
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

Growth Ratios

	Immunitybio Inc (IBRX)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Halozyme Therapeutics (HALO)
Revenue Growth (%)	192.92	24.67	114.85	9.23	41.15
EBIT Growth (%)	-257.67	18.70	136.39	29.37	-14.99
Net Profit Growth (%)	-170.33	17.50	378.76	42.89	-25.78
EPS Growth (%)	-110.92	26.84	353.27	50.42	-23.48
Book Value Growth (%)	-55.11	164.02	816.12	-0.70	-55.81

Valuation Ratios

	Immunitybio Inc (IBRX)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Halozyme Therapeutics (HALO)
Price / Earnings	-5.58	36.06	-59.76	15.79	24.99
Price / Book Value	-3.92	35.44	-80.42	5.72	162.23
Dividend Yield (%)	--	--	--	--	--
EV/EBITDA	-11.61	27.88	-121.54	12.44	17.31
Market Cap ($ Cr)	--	--	--	--	--

Solvency Ratios

	Immunitybio Inc (IBRX)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Halozyme Therapeutics (HALO)
Debt to Equity	-0.74	0.00	0.27	0.00	13.50
Short term debt to equity ratio	-0.01	0.06	0.05	0.00	1.46
Current Ratio	5.72	0.73	2.99	3.46	2.71
Quick Ratio	5.70	0.73	2.32	3.38	2.31
Interest Coverage	-10.92	--	1.62	--	29.73

Operating Efficiency Ratios

	Immunitybio Inc (IBRX)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Halozyme Therapeutics (HALO)
Debtors to sales (%)	32.25	15.88	21.25	13.74	27.40
Asset Turnover	0.29	0.89	0.44	0.83	0.65
Receivable days	72.98	50.42	85.52	43.48	98.04
Inventory Days	2,226.91	--	1,056.70	96.17	254.12
Payable days	3,323.39	6.26	331.01	147.97	24.86
Cash Conversion Cycle	-1,023.50	--	811.21	-8.32	327.29

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly